Investors & Media

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Report Third Quarter 2017 Financial Results on Thursday, November 2, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 24, 2017-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast
View HTML
Toggle Summary Sage Therapeutics to Participate in Leerink Investor Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 22, 2017-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will participate in the Leerink Partners Rare
View HTML
Toggle Summary Sage Therapeutics Reports Top-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus
-- Study did not achieve its primary endpoint in first-of-its kind trial for patients suffering from life-threatening seizure condition -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 12, 2017-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to
View HTML
Toggle Summary Sage Therapeutics to Present at Morgan Stanley Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 7, 2017-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas , M.D., Chief Executive Officer of Sage, will
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on September 1, 2017 , the Compensation Committee of Sage's Board of Directors
View HTML
Toggle Summary Sage Therapeutics Announces Second Quarter 2017 Financial Results and Provides Pipeline Update
Enrollment completed in Phase 3 STATUS Trial of brexanolone in SRSE; reiterate Q3 2017 guidance for top-line results Positive scientific advice from European Medicines Agency on development of brexanolone in PPD provides regulatory path in EU Updated guidance for SAGE-217 Phase 2 placebo-controlled
View HTML
Toggle Summary Sage Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday,
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on July 3, 2017 , the Compensation Committee of Sage's Board of Directors
View HTML
Toggle Summary Sage Therapeutics Announces The Lancet Publishes Positive Phase 2 Brexanolone (SAGE-547) Clinical Data in Severe Postpartum Depression
- Study showed significant mean reduction in the 17-item Hamilton Rating Scale for Depression (HAM-D) total score compared to placebo - - Seventy percent of subjects in the study experienced remission of symptoms within 60 hours of treatment with brexanolone and maintained effect until 30-day
View HTML
Toggle Summary Sage Therapeutics to Present at Goldman Sachs Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas , M.D., Chief Executive Officer of Sage, will present at the
View HTML